Human Telomerase Reverse Transcriptase (hTERT): A target molecule for the treatment of cisplatin-resistant tumors

Korean Journal of Laboratory Medicine

Volumn 28, Issue 6, 2008, Pages 430-437

  Park, Yuk Pheel ^a   Kim, Kwang Dong ^b   Kang, Seong Ho ^c   Yoon, Do Young ^d   Park, Joo Won ^e   Kim, Jong Wan ^e   Lee, Hee Gu ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Gyeongsang National University   (South Korea)

^c Chonbuk National University   (South Korea)

^d Konkuk University   (South Korea)

^e Dankook University   (South Korea)

Author keywords

Apoptosis; Bladder cancer; Caspase; Cisplatin; hTERT

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYL ALANYL ASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CASPASE; CISPLATIN; CYSTEINE PROTEINASE INHIBITOR; CYTOCHROME C; CYTOCHROME C''; PEPTIDE CHLOROMETHYL KETONE; PROTEIN BAX; SMALL INTERFERING RNA; TELOMERASE; TERT PROTEIN, HUMAN;

ARTICLE; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; NEOPLASM; TUMOR CELL LINE;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE, TUMOR; CISPLATIN; CYSTEINE PROTEINASE INHIBITORS; CYTOCHROME C GROUP; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RNA, SMALL INTERFERING; TELOMERASE;

EID: 62349130927     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2008.28.6.430     Document Type: Article

References (35)

1. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
2. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79. (Pubitemid 37487159)
3. Roth BJ and Bajorin DF. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 1995;153:894-900.
4. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984;100: 19-24. (Pubitemid 14219123)
5. Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr, Siddik ZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)( trans-diacetato)(dichloro)- platinum(IV). Clin Cancer Res 1999; 5:655-63. (Pubitemid 29131977)
6. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication problem and cell aging. J Mol Biol 1992;225:951-60.
7. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269: 1236-41.
8. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-95. (Pubitemid 27357969)
9. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-9. (Pubitemid 27366681)
10. Lingner J and Cech TR. Telomerase and chromosome end maintenance. Curr Opin Genet Dev 1998;8:226-32. (Pubitemid 28206287)
11. Nugent CI and Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev 1998;12:1073-85. (Pubitemid 28194043)
12. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-52. (Pubitemid 28063364)
13. Muller M. Telomerase: its clinical relevance in the diagnosis of bladder cancer. Oncogene 2002;21:650-5. (Pubitemid 34146267)
14. Heine B, Hummel M, Muller M, Heicappell R, Miller K, Stein H. Non-radioactive measurement of telomerase activity in human bladder cancer, bladder washings, and in urine. J Pathol 1998;184:71-6. (Pubitemid 28086156)
15. Ito H, Kyo S, Kanaya T, Takakura M, Koshida K, Namiki M, et al. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 1998;4:2807-10. (Pubitemid 28523509)
16. Dettlaff-Pokora A, Matuszewski M, Schlichtholz B. Telomerase activity in urine sediments as a tool for noninvasive detection of bladder cancer. Cancer Lett 2005;222:83-8. (Pubitemid 40544850)
17. Wong KK, Chang S, Weiler SR, Ganesan S, Chaudhuri J, Zhu C, et al. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet 2000;26:85-8.
18. Chen Z, Koeneman KS, Corey DR. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res 2003;63:5917-25. (Pubitemid 37187493)
19. Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K, et al. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res 2002;8:3341-47. (Pubitemid 35340707)
20. Ward RJ and Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol 2005;68:779-86. (Pubitemid 41206032)
21. Lee ES, Min KJ, Kim SW, Lee HW, Cho KS, Kim KM, et al. Change of chemosensitivity and cellular characteristics of cisplatinum resistant human bladder cancer cells induced by long-term cisplatinum treatment. Korean J Urol 1998;39:305-10.
22. Kim JK, Kim KD, Lee E, Lim JS, Cho HJ, Yoon HK, et al. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett 2004;212:61-70. (Pubitemid 38887721)
23. Cho HJ, Kim JK, Kim KD, Yoon HK, Cho MY, Park YP, et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 2006;237:56-66.
24. Mandal M and Kumar R. Bcl-2 modulates telomerase activity. J Biol Chem 1997;272:14183-7. (Pubitemid 27232827)
25. Melissourgos N, Kastrinakis NG, Davilas I, Foukas P, Farmakis A, Lykourinas M. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology 2003;62:362-7. (Pubitemid 36952107)
26. Zou L, Zhang P, Luo C, Tu Z. shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother Pharmacol 2006;57:328-34.
27. Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci U S A 1999;96:14276-81. (Pubitemid 30000641)
28. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 2001;19:114-20. (Pubitemid 32155432)
29. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5:1164-70. (Pubitemid 29474421)
30. Schindler A, Fiedler U, Meye A, Schmidt U, Fussel S, Pilarsky C, et al. Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro. Int J Oncol 2001;19:25-30.
31. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001;20:6958-68. (Pubitemid 34062288)
32. Kondo Y, Koga S, Komata T, Kondo S. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 2000;19:2205-11. (Pubitemid 30307186)
33. Koga S, Kondo Y, Komata T, Kondo S. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther 2001;8:654-8. (Pubitemid 32422061)
34. Saretzki G, Ludwig A, von Zglinicki T, Runnebaum IB. Ribozymemediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther 2001; 8:827-34. (Pubitemid 32983139)
35. Cao Y, Li H, Deb S, Liu JP. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 2002;21:3130-8. (Pubitemid 34548084)